DDInter1940 DDInter1112
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the E
Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Vismodegib {u} (Compound) resembles {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Vismodegib {u} (Compound) resembles {v} (Compound) Sorafenib
Sorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Raltegravir {u} may lead to a major life threatening interaction when taken with {v} Magaldrate
Vismodegib {u} (Compound) resembles {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Indomethacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Vismodegib {u} (Compound) resembles {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluoperazine
Trifluoperazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Vismodegib {u} (Compound) resembles {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Diflunisal {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Vismodegib {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Captopril
Captopril {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Vismodegib {u} (Compound) resembles {v} (Compound) Sorafenib
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Thioridazine
Thioridazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Vismodegib {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Eltrombopag
Eltrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Vismodegib {u} (Compound) resembles {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Vismodegib {u} (Compound) resembles {v} (Compound) Sulfasalazine
Sulfasalazine {u} may lead to a major life threatening interaction when taken with {v} Methenamine
Methenamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Vismodegib (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Vismodegib (Compound) resembles Sorafenib (Compound) and Sorafenib may cause a minor interaction that can limit clinical effects when taken with Raltegravir and Raltegravir may lead to a major life threatening interaction when taken with Magaldrate
Vismodegib (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Vismodegib (Compound) resembles Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Vismodegib (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Vismodegib (Compound) binds ALB (Gene) and ALB (Gene) is bound by Captopril (Compound) and Captopril may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Vismodegib (Compound) resembles Sorafenib (Compound) and Sorafenib may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Vismodegib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Eltrombopag (Compound) and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Vismodegib (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Vismodegib (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may lead to a major life threatening interaction when taken with Methenamine and Methenamine may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate